|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MIS18BP1 |
Gene summary for MIS18BP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MIS18BP1 | Gene ID | 55320 |
| Gene name | MIS18 binding protein 1 | |
| Gene Alias | C14orf106 | |
| Cytomap | 14q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0007049 | UniProtAcc | Q6P0N0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55320 | MIS18BP1 | LZE2T | Human | Esophagus | ESCC | 8.76e-10 | 7.54e-01 | 0.082 |
| 55320 | MIS18BP1 | LZE4T | Human | Esophagus | ESCC | 1.51e-13 | 3.61e-01 | 0.0811 |
| 55320 | MIS18BP1 | LZE5T | Human | Esophagus | ESCC | 4.41e-05 | 5.67e-01 | 0.0514 |
| 55320 | MIS18BP1 | LZE7T | Human | Esophagus | ESCC | 1.92e-06 | 3.68e-01 | 0.0667 |
| 55320 | MIS18BP1 | LZE8T | Human | Esophagus | ESCC | 7.49e-05 | 1.27e-01 | 0.067 |
| 55320 | MIS18BP1 | LZE20T | Human | Esophagus | ESCC | 1.23e-03 | 2.89e-01 | 0.0662 |
| 55320 | MIS18BP1 | LZE24T | Human | Esophagus | ESCC | 9.14e-16 | 3.64e-01 | 0.0596 |
| 55320 | MIS18BP1 | LZE22D3 | Human | Esophagus | HGIN | 2.44e-02 | 3.78e-01 | 0.0653 |
| 55320 | MIS18BP1 | LZE21T | Human | Esophagus | ESCC | 4.29e-03 | 2.81e-01 | 0.0655 |
| 55320 | MIS18BP1 | LZE6T | Human | Esophagus | ESCC | 2.07e-02 | 1.25e-01 | 0.0845 |
| 55320 | MIS18BP1 | P1T-E | Human | Esophagus | ESCC | 2.51e-13 | 5.93e-01 | 0.0875 |
| 55320 | MIS18BP1 | P2T-E | Human | Esophagus | ESCC | 1.57e-30 | 7.38e-01 | 0.1177 |
| 55320 | MIS18BP1 | P4T-E | Human | Esophagus | ESCC | 1.39e-23 | 7.23e-01 | 0.1323 |
| 55320 | MIS18BP1 | P5T-E | Human | Esophagus | ESCC | 1.14e-39 | 8.22e-01 | 0.1327 |
| 55320 | MIS18BP1 | P8T-E | Human | Esophagus | ESCC | 5.08e-34 | 6.38e-01 | 0.0889 |
| 55320 | MIS18BP1 | P9T-E | Human | Esophagus | ESCC | 6.22e-15 | 4.48e-01 | 0.1131 |
| 55320 | MIS18BP1 | P10T-E | Human | Esophagus | ESCC | 3.83e-38 | 7.36e-01 | 0.116 |
| 55320 | MIS18BP1 | P11T-E | Human | Esophagus | ESCC | 2.73e-07 | 3.00e-01 | 0.1426 |
| 55320 | MIS18BP1 | P12T-E | Human | Esophagus | ESCC | 2.50e-23 | 5.09e-01 | 0.1122 |
| 55320 | MIS18BP1 | P15T-E | Human | Esophagus | ESCC | 5.24e-19 | 5.70e-01 | 0.1149 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Stomach | WIM |  |
| Stomach | SIM |  |
| Liver | NAFLD |  |
| Liver | Cirrhotic |  |
| Liver | HCC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MIS18BP1 | SNV | Missense_Mutation | c.2194N>C | p.Glu732Gln | p.E732Q | Q6P0N0 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD | |
| MIS18BP1 | SNV | Missense_Mutation | novel | c.609N>T | p.Lys203Asn | p.K203N | Q6P0N0 | protein_coding | tolerated(0.07) | benign(0.031) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MIS18BP1 | SNV | Missense_Mutation | c.862N>G | p.Leu288Val | p.L288V | Q6P0N0 | protein_coding | tolerated(0.5) | benign(0.024) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MIS18BP1 | SNV | Missense_Mutation | novel | c.917G>A | p.Ser306Asn | p.S306N | Q6P0N0 | protein_coding | tolerated(0.43) | benign(0.021) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| MIS18BP1 | SNV | Missense_Mutation | novel | c.1754T>G | p.Ile585Ser | p.I585S | Q6P0N0 | protein_coding | tolerated(0.29) | benign(0.017) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MIS18BP1 | SNV | Missense_Mutation | c.2702G>T | p.Gly901Val | p.G901V | Q6P0N0 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-BH-A0DQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MIS18BP1 | SNV | Missense_Mutation | novel | c.3161G>T | p.Cys1054Phe | p.C1054F | Q6P0N0 | protein_coding | tolerated(0.18) | benign(0.367) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| MIS18BP1 | SNV | Missense_Mutation | c.2581N>C | p.Asp861His | p.D861H | Q6P0N0 | protein_coding | tolerated(0.06) | benign(0.201) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MIS18BP1 | SNV | Missense_Mutation | c.2579C>G | p.Ser860Cys | p.S860C | Q6P0N0 | protein_coding | deleterious(0.04) | benign(0.01) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| MIS18BP1 | SNV | Missense_Mutation | c.29N>C | p.Arg10Thr | p.R10T | Q6P0N0 | protein_coding | tolerated(0.11) | benign(0.043) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |